Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 42

1.

Food and Drug Administration perspective on negative symptoms in schizophrenia as a target for a drug treatment claim.

Laughren T, Levin R.

Schizophr Bull. 2006 Apr;32(2):220-2. Epub 2005 Aug 3.

PMID:
16079389
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Exploratory analyses of efficacy data from schizophrenia trials in support of new drug applications submitted to the US Food and Drug Administration.

Khin NA, Chen YF, Yang Y, Yang P, Laughren TP.

J Clin Psychiatry. 2012 Jun;73(6):856-64. doi: 10.4088/JCP.11r07539. Epub 2012 May 15. Review.

PMID:
22687813
[PubMed - indexed for MEDLINE]
3.

Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.

Woods SW, Gueorguieva RV, Baker CB, Makuch RW.

Arch Gen Psychiatry. 2005 Sep;62(9):961-70. Review.

PMID:
16143728
[PubMed - indexed for MEDLINE]
4.

An industry perspective on the NIMH consensus statement on negative symptoms.

Alphs L.

Schizophr Bull. 2006 Apr;32(2):225-30. Epub 2006 Feb 9.

PMID:
16469940
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Management of the negative symptoms of schizophrenia: new treatment options.

Möller HJ.

CNS Drugs. 2003;17(11):793-823. Review.

PMID:
12921492
[PubMed - indexed for MEDLINE]
6.

Clinical trials with a new atypical antipsychotic (Aripiprazole): gender specific information analysis.

Montero I, Talavera M, Ruiz I.

Women Health. 2008;47(4):39-51. doi: 10.1080/03630240802100051. Review.

PMID:
18843939
[PubMed - indexed for MEDLINE]
7.

Modafinil as an adjunctive treatment of sedation, negative symptoms, and cognition in schizophrenia: a critical review.

Saavedra-Velez C, Yusim A, Anbarasan D, Lindenmayer JP.

J Clin Psychiatry. 2009 Jan;70(1):104-12. Epub 2008 Nov 18. Review.

PMID:
19026265
[PubMed - indexed for MEDLINE]
8.

Randomized controlled trials in schizophrenia: opportunities, limitations, and trial design alternatives.

Correll CU, Kishimoto T, Kane JM.

Dialogues Clin Neurosci. 2011;13(2):155-72. Review.

PMID:
21842613
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Oral antipsychotic update: a brief review of new and investigational agents for the treatment of schizophrenia.

Citrome L.

CNS Spectr. 2012 Nov;17 Suppl 1:1-9. doi: 10.1017/S1092852912000727. Review.

PMID:
23448847
[PubMed - indexed for MEDLINE]
10.

Novel antipsychotics and negative symptoms.

Möller HJ.

Int Clin Psychopharmacol. 1998 Mar;13 Suppl 3:S43-7. Review.

PMID:
9690970
[PubMed - indexed for MEDLINE]
11.

Ziprasidone: an atypical antipsychotic drug for the treatment of schizophrenia.

Stimmel GL, Gutierrez MA, Lee V.

Clin Ther. 2002 Jan;24(1):21-37. Review.

PMID:
11833834
[PubMed - indexed for MEDLINE]
12.

New antipsychotic medications: strategies for evaluation and selected findings.

Schooler NR.

Schizophr Res. 1997 Oct 30;27(2-3):249-59. Review.

PMID:
9416654
[PubMed - indexed for MEDLINE]
13.

Adjunct mirtazapine for negative symptoms of schizophrenia.

Phan SV, Kreys TJ.

Pharmacotherapy. 2011 Oct;31(10):1017-30. doi: 10.1592/phco.31.10.1017. Review.

PMID:
21950644
[PubMed - indexed for MEDLINE]
14.

Antidepressants as add-on treatment to antipsychotics for people with schizophrenia and pronounced negative symptoms: a systematic review of randomized trials.

Rummel C, Kissling W, Leucht S.

Schizophr Res. 2005 Dec 1;80(1):85-97. Epub 2005 Sep 22. Review.

PMID:
16183258
[PubMed - indexed for MEDLINE]
15.

Efficacy, safety, and tolerability of quetiapine in patients with schizophrenia.

Nasrallah HA, Tandon R.

J Clin Psychiatry. 2002;63 Suppl 13:12-20. Review.

PMID:
12562142
[PubMed - indexed for MEDLINE]
16.

Identifying cognitive mechanisms targeted for treatment development in schizophrenia: an overview of the first meeting of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia Initiative.

Carter CS, Barch DM, Buchanan RW, Bullmore E, Krystal JH, Cohen J, Geyer M, Green M, Nuechterlein KH, Robbins T, Silverstein S, Smith EE, Strauss M, Wykes T, Heinssen R.

Biol Psychiatry. 2008 Jul 1;64(1):4-10. doi: 10.1016/j.biopsych.2008.03.020. Epub 2008 May 7.

PMID:
18466880
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Selective serotonin reuptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia.

Silver H.

Int Clin Psychopharmacol. 2003 Nov;18(6):305-13. Review.

PMID:
14571150
[PubMed - indexed for MEDLINE]
18.

Cognitive behavior therapy for schizophrenia.

Turkington D, Kingdon D, Weiden PJ.

Am J Psychiatry. 2006 Mar;163(3):365-73. Review.

PMID:
16513854
[PubMed - indexed for MEDLINE]
19.

The role of atypical antipsychotic agents in the treatment of schizophrenia and schizoaffective disorders in the elderly.

Madhusoodanan S, Sinha A, Sajatovic M, Gupta S, Brenner R.

Curr Drug Saf. 2006 Aug;1(3):227-41. Review.

PMID:
18690933
[PubMed - indexed for MEDLINE]
20.

Randomized controlled trials for schizophrenia: study designs targeted to distinct goals.

Stroup TS, Geddes JR.

Schizophr Bull. 2008 Mar;34(2):266-74. doi: 10.1093/schbul/sbm156. Epub 2008 Jan 31. Review.

PMID:
18245060
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk